Moreover, adjuvant immunotherapy with atezolizumab was also reported to improve the overall survival of patients whose stage II-IIIA tumors expressed PDL-1 on ≥50% of tumor cells (exploratory analysis of a secondary endpoint), with a hazard ratio of 0.43 (95% CI 0.24–0.78). This evidence concerns the gene CD274 and neoplasm.